Fig. 5From: A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancerT-PNU anti-tumor protection is CD8 T cell-dependent. a, Tumor growth curves of EMT6-hHER2 tumor-bearing animals upon treatment with T-PNU (1 mg/kg, 2x), α-CD8 (10 mg/kg), or α-CD8 followed by T-PNU treatment, P-value < 0.0001 *** (Gehan-Breslow-Wilcoxon Test). b, Overall survival curves of aBack to article page